<DOC>
	<DOCNO>NCT00409032</DOCNO>
	<brief_summary>The primary objective study compare dose-response effect three dose level strontium malonate placebo bone resorption quantify S-CTX-1 follow 12 week treatment .</brief_summary>
	<brief_title>A Dose-response Study With Strontium Malonate Postmenopausal Women</brief_title>
	<detailed_description>275 post menopausal woman treat either 750 mg strontium malonate , 1000 mg strontium malonate , 2000 mg strontium malonate , 2 g ProtelosÂ® placebo . Patients treat 12 week . A follow period 4 week plan main study follow period 8 week plan approximately 20 % patient follow post treatment CTX-1 activity . Apart S-CTS-1 also response bio marker evaluate well BMD .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Postmenopausal woman ( least 12 month since last menstruation ) . BMD ( L24 ) Tscore 1 3 ( least 20 % enrolled patient must BMD ( L24 ) Tscore 2,5 ) . 50 year age . BMI &lt; 30 kg/m2 . Total SCa level within normal range . Ability read understand information give . The patient sign informed consent form accord ICH E6 local requirement study specific procedure carry . Ability comply study procedure . History prior fragility fracture ( fracture wrist , hip spine appear 40 year age ) . History alcohol drug abuse . Metabolic bone disease ( e.g . paget disease , bone cancer ) . History VTE/DVT . History kidney transplant . Bilateral oophorectomy . Relevant treat reduced kidney liver function . Any malignancy within last 5 year ( except basal cell carcinoma ) Any chronic condition likely affect absorption ( e.g . Crohns disease , gluten enteropathy ) . Known genetic predisposition VTE/DVT Known hypersensitivity active substance excipients . 25OHvitamin D level 25 nmol/L Any previous treatment bisphosphonates , Strontium fluoride . Treatment last 3 month affect calcium balance bone metabolism ( e.g . thiazide , corticosteroid , calcitonin , HRT , SERMs , PTH , phosphorus ) . Treatment last week tetracycline , ciprofloxacin loop diuretic . PTH normal range Use drug know influence coagulation process ( aspirin NSAID allow ) Prothrombin time normal range ( sec INR ) Inclusion another clinical study within 30 day randomization study</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>BMD</keyword>
	<keyword>CTX</keyword>
	<keyword>Post menopausal</keyword>
	<keyword>strontium</keyword>
	<keyword>bone turnover</keyword>
	<keyword>clinical development</keyword>
</DOC>